

## 5. References

1. Tanaka Y, Saito Y. Importance of NUDT15 Polymorphisms in Thiopurine Treatments. *J Pers Med*. 2021;11(8).
2. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. *Pediatr Int*. 2018;60(1):4-12.
3. Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. *Clin Pharmacol Ther*. 2019;105(5):1095-105.
4. Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. *Nat Genet*. 2014;46(9):1017-20.
5. Ali AM, Adam H, Hailu D, Engidawork E, Howe R, Abula T, et al. Genetic variants of genes involved in thiopurine metabolism pathway are associated with 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia patients from Ethiopia. *Front Pharmacol*. 2023;14:1159307.
6. Wahlund M, Nilsson A, Kahlin AZ, Broliden K, Myrberg IH, Appell ML, et al. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia. *J Pediatr*. 2020;216:150-7.e1.
7. Tanaka Y, Nakadate H, Kondoh K, Nakamura K, Koh K, Manabe A. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. *Pharmacogenomics J*. 2018;18(2):275-80.
8. Zhou H, Li L, Yang P, Yang L, Zheng JE, Zhou Y, et al. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia:

NUDT15, TPMT, or ITPA genetic variants? BMC Cancer. 2018;18(1):516.

9. Kim H, Seo H, Park Y, Min BJ, Seo ME, Park KD, et al. APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia. Cancer Res Treat. 2018;50(3):823-34.
10. Buaboonnam J, Sripatanatadasakul P, Treesucon A, Glomglao W, Siraprapapat P, Narkbunnam N, et al. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia. Pediatr Int. 2019;61(8):754-8.
11. Puangpetch A, Tiyasirichokchai R, Pakakasama S, Wiwattanakul S, Anurathapan U, Hongeng S, et al. NUDT15 genetic variants are related to thiopurine-induced neutropenia in Thai children with acute lymphoblastic leukemia. Pharmacogenomics. 2020;21(6):403-10.
12. Cao M, Yin D, Qin Y, Liao F, Su Y, Xia X, et al. Screening of Novel Pharmacogenetic Candidates for Mercaptopurine-Induced Toxicity in Patients With Acute Lymphoblastic Leukemia. Front Pharmacol. 2020;11:267.
13. Zhou Y, Wang L, Zhai XY, Wen L, Tang F, Yang F, et al. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2020;86(8):1519-27.
14. Boonyawat B, Monsereenusorn C, Photia A, Lertvivatpong N, Kaewchaivijit V, Jindatanmanusan P, et al. ITPA:c.94C>A and NUDT15:c.415C>T Polymorphisms and Their Relation to Mercaptopurine-Related Myelotoxicity in Childhood Leukemia in Thailand. Appl Clin Genet. 2021;14:341-51.
15. Mao X, Yin R, Sun G, Zhou Y, Yang C, Fang C, et al. Effects of TPMT, NUDT15, and ITPA Genetic Variants on 6-Mercaptopurine Toxicity for Pediatric Patients With Acute Lymphoblastic Leukemia in Yunnan of China. Front Pediatr. 2021;9:719803.
16. Nghia H, Than HH, Dong CV, Oanh TTK, Truc VTT, Ngan CTT, et al. The effects of NUDT15 and TPMT variants on mercaptopurine treatment in Vietnamese pediatric acute

lymphoblastic leukemia patients. *Pediatr Hematol Oncol.* 2022;39(6):561-70.

17. Khaeso K, Komvilaisak P, Chainansamit SO, Nakkam N, Suwannaying K, Kuwatjanakul P, et al. NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine. *Drug Metab Pharmacokinet.* 2022;43:100436.

18. Fan POL, Leung KT, Chan KYY, Leung AWK, Lam GKS, Chow TTW, et al. ABCC4, ITPA, NUDT15, TPMT and their interaction as genetic predictors of 6-mercaptopurine intolerance in chinese patients with acute lymphoblastic leukemia. *Pediatr Hematol Oncol.* 2022;39(3):254-66.

19. Nguyen ML, Hoang AV, Duong BT, Phung NTN. The influence of NUDT15 variants on 6-mercaptopurine-induced neutropenia in Vietnamese pediatric acute lymphoblastic leukemia. *HGG Adv.* 2023;4(2):100183.

20. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020;581(7809):434-43.

21. Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. *Cancer Chemother Pharmacol.* 2019;83(2):341-8.

22. Zgheib NK, Akika R, Mahfouz R, Aridi CA, Ghanem KM, Saab R, et al. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon. *Pediatr Blood Cancer.* 2017;64(1):146-50.

23. Correa-Jimenez O, Yunis JJ, Linares-Ballesteros A, Sarmiento-Urbina I. Susceptibility to thiopurine toxicity by TPMT and NUDT15 variants in Colombian children with acute

lymphoblastic leukemia. Colomb Med (Cali). 2021;52(3):e2074569.

24. Ferreira GMA, Ribeiro Elias AB, Nascimento J, Monteiro WM, Melo GC, Baia-da-Silva DC, et al. Pharmacogenomics of thiopurines: distribution of TPMT and NUDT15 polymorphisms in the Brazilian Amazon. Pharmacogenet Genomics. 2020;30(8):184-9.

25. Chikondowa P, Munkombwe D, Chikwambi Z, Kuona P, Masimirembwa C. Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia. Pharmacogenomics. 2023;24(8):449-57.